HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.

Abstract
Epidermal growth factor receptor (EGFR) mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation frequency on lung adenocarcinoma is still limited to retrospective studies. The PIONEER study (NCT01185314) is a prospective molecular epidemiology study in Asian patients with newly diagnosed advanced lung adenocarcinoma, aiming to prospectively analyze EGFR mutation status in IIIB/IV treatment-naïve lung adenocarcinomas in Asia. We report the mainland China subset results. Eligible patients (≥20 yrs old, IIIB/IV adenocarcinoma and treatment-naïve) were registered in 17 hospitals in mainland China. EGFR was tested for mutations by amplification refractory mutation system using biopsy samples. Demographic and clinical characteristics were collected for subgroup analyses. A total of 747 patients were registered. Successful EGFR mutation analysis was performed in 741, with an overall mutation rate of 50.2%. The EGFR active mutation rate is 48.0% (with 1.3% of combined active and resistance mutations). Tobacco use (>30 pack-year vs. 0-10 pack-year, OR 0.27, 95%CI: 0.17-0.42) and regional lymph nodes involvement (N3 vs. N0, OR 0.47, 95%CI: 0.29-0.76) were independent predictors of EGFR mutation in multivariate analysis. However, even in regular smokers, the EGFR mutation frequency was 35.3%. The EGFR mutation frequency was similar between diverse biopsy sites and techniques. The overall EGFR mutation frequency of the mainland China subset was 50.2%, independently associated with the intensity of tobacco use and regional lymph nodes involvement. The relatively high frequency of EGFR mutations in the mainland China subset suggest that any effort to obtain tissue sample for EGFR mutation testing should be encouraged.
AuthorsYuankai Shi, Junling Li, Shucai Zhang, Mengzhao Wang, Shujun Yang, Ning Li, Gang Wu, Wei Liu, Guoqing Liao, Kaican Cai, Liang'an Chen, Meizhen Zheng, Ping Yu, Xiuwen Wang, Yunpeng Liu, Qisen Guo, Ligong Nie, Jiwei Liu, Xiaohong Han
JournalPloS one (PLoS One) Vol. 10 Issue 11 Pg. e0143515 ( 2015) ISSN: 1932-6203 [Electronic] United States
PMID26599344 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • EGFR protein, human
  • ErbB Receptors
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Asian People
  • Carcinoma, Non-Small-Cell Lung (genetics)
  • China
  • ErbB Receptors (genetics)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Molecular Epidemiology (methods)
  • Mutation
  • Retrospective Studies
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: